Optiver Holding
CRSP icon

Optiver Holding’s CRISPR Therapeutics CRSP Stock Holding History

Optiver Holding’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$28.6K Buy
525
+187
+55% +$9.86K ﹤0.01% 1365
2026
Q1 		$16.1K Buy
338
+19
+6% +$1K ﹤0.01% 1137
2025
Q4 		$16.7K Sell
319
-185
-37% -$11.1K ﹤0.01% 1058
2025
Q3 		$32.7K Buy
504
+210
+71% +$12.1K ﹤0.01% 855
2025
Q2 		$14.3K Buy
+294
New +$11.4K ﹤0.01% 913

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
GP
GSK plc London $602M AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Optiver Holding's CRSP Position: Q2 2026 in Review

Optiver Holding increased its CRISPR Therapeutics (CRSP) stake by 55% in Q2 2026, buying an estimated $9.86K and bringing the position to 525 shares worth $28.6K. The position accounts for ﹤0.01% of the portfolio, ranked #1365.

Optiver Holding first reported a position in CRSP in Q2 2025 and has held it in 5 quarters since. The position peaked at $32.7K in Q3 2025. 524 funds tracked by Wall St. Rank hold CRSP as of Q2 2026.

  • Optiver Holding held 525 shares of CRISPR Therapeutics worth $28.6K as of Q2 2026.
  • Optiver Holding bought 187 CRISPR Therapeutics shares in Q2 2026, an estimated $9.86K.
  • CRISPR Therapeutics made up ﹤0.01% of Optiver Holding's portfolio in Q2 2026, its #1365 holding.
  • Optiver Holding first reported a position in CRISPR Therapeutics in Q2 2025 and has held it in 5 quarters since.
  • Optiver Holding's CRISPR Therapeutics position peaked at $32.7K in Q3 2025.
  • 524 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2026.

Based on Optiver Holding's 13F filing for Q2 2026, filed 12 Aug 2026.